文献速递膀胱癌与上尿路尿路上皮癌

放疗联合放射增敏剂治疗卡介苗无应答的非肌层浸润性原位膀胱癌:一项开放标签、单臂、多中心、2期欧洲癌症研究与治疗组织试验

Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial.
PubMed 文献 · Eur Urol Oncol · 2024-03-30

该研究为多中心、前瞻性、国际、2期试验,评估中度大分割放疗联合放射增敏剂在卡介苗无应答的非肌层浸润性原位膀胱癌且不适合或拒绝根治性膀胱切除术患者中的疗效。主要终点为6个月完全缓解率,定义为对照膀胱活检无原位癌证据。次要终点包括总生存、无进展生存、完全缓解持久性、3-4级不良事件率、生活质量和器官保留率。

要点

  • 根治性膀胱切除加盆腔淋巴结清扫和尿流改道是卡介苗无应答非肌层浸润性膀胱癌的标准治疗。
  • 该2期试验入组不适合或拒绝根治性膀胱切除术的卡介苗无应答原位癌患者。
  • 主要终点为6个月完全缓解率,定义为对照膀胱活检无原位癌证据。

核心结论

  • 研究将评估外照射放疗联合放射增敏剂在卡介苗无应答非肌层浸润性原位膀胱癌患者中的疗效,并测量6个月及之后无复发患者的比例,同时评估安全性和对生活质量的影响。

研究设计与样本

  • 欧洲癌症研究与治疗组织(EORTC)2235研究(NCT06310369)为多中心、前瞻性、国际、2期试验,评估中度大分割放疗联合放射增敏剂治疗卡介苗无应答的非肌层浸润性原位膀胱癌且不适合或拒绝根治性膀胱切除术的患者。
  • 接受过nadofaragene firadenovec或TAR-200的患者符合入组条件。

关键数值与推荐

  • 主要终点为6个月完全缓解率,定义为对照膀胱活检无原位癌证据。
  • 次要终点包括总生存、无进展生存、完全缓解持久性、3-4级不良事件率、患者生活质量和器官保留率。
  • 放疗每周5天,持续4周,期间联合放射增敏剂(静脉或口服药物)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radical cystectomy with pelvic lymph node dissection and urinary diversion is the standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). However, many patients are unwilling or unable to undergo such major surgery associated with high morbidity and a negative impact on quality of life. Chemoradiotherapy is an established treatment option for muscle-invasive bladder cancer. However, it has not been investigated adequately in NMIBC until now. The European Organisation for Research and Treatment of Cancer (EORTC) 2235 study (NCT06310369) is designed as a multicenter, prospective, international, phase 2 trial of moderate hypofractionated radiotherapy combined with a radiosensitizer in BCG-unresponsive NMIBC patients with carcinoma in situ (CIS) who are not eligible for or declined to undergo radical cystectomy. Patients who have received nadofaragene firadenovec or TAR-200 are eligible. The primary endpoint is the 6-mo complete response (CR) rate defined by the absence of CIS proven by a control biopsy of the bladder. The secondary endpoints include overall survival, progression-free survival, durability of CR, grade 3-4 adverse events rate, patients' quality of life, and organ preservation rate. PATIENT SUMMARY: Intravesical instillation of bacillus Calmette-Guérin is the standard treatment of non-muscle-invasive, also coined as superficial, bladder cancer. In case the cancer recurs, even superficially, there is no other proven treatment than a radical cystectomy-the surgical removal of the bladder. Although the surgical technique has improved dramatically over the past few years, it remains contraindicated in patients with severe comorbidities. In addition, because it affects the quality of life, patients may reject this option. This study will assess the efficacy of external beam radiotherapy, a robust alternative to surgery in muscle-invasive bladder cancer. Radiotherapy will be administered 5 d a week for 4 wk. It will be associated with a "radiosensitizer," an intravenous or oral drug, during the radiotherapy treatment. The study will measure the proportion of patients remaining recurrence free at 6 mo and thereafter. It will also evaluate the safety of the treatment and its impact on quality of life.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Achard V, Fournier B, D'Haese D, et al. Radiotherapy Combined with a Radiosensitizer for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Carcinoma In Situ Bladder Cancer: An Open-label, Single-arm, Multicenter, Phase 2 European Organisation for Research and Treatment of Cancer Trial. Eur Urol Oncol. 2024. PMID: 38556413. doi:10.1016/j.euo.2024.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。